Clinical Trial Update: Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different Formulations of GSK Bio Hep B Vaccine [Phase 4]

View source ↗

Summary

This Phase 4 trial evaluates immune response approximately 5 to 6 years after receiving different formulations of GSK's Hepatitis B vaccine; the study has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Engerix-B (hepatitis B vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B | Phase 4 | Status: COMPLETED